Considering that SARS-CoV-2 specifically binds to human ACE2, not to murine ACE2 [30], a transgenic murine model expressing K18-hACE2 was developed [31] and is widely used as an efficacy evaluation model for developing COVID-19 treatments [32–34]. This evidence concerns the gene ACE2 and COVID-19.